Comparison of UBE2E3-Ab levels in HDs and patients with cancer
Sample information and alpha analysis
(A) Sample information
HD
GC
CRC
EC
Total sample number
95
94
96
95
Male/Female
51/44
73/21
66/30
57/38
Age (average ± SD)
57.9 ± 6.0
66.6 ± 9.1
66.6 ± 9.7
67.2 ± 11.6
(B) Alpha analysis (antibody level)
UBE2E3-Ab
DAN-Ab
SOSTDC1-Ab
HD
Average
9,193
218,241
18,075
SD
6,267
75,817
13,567
Cutoff value
21,728
369,876
45,208
Positive No.
5
4
4
Positive rate (%)
5.3%
4.2%
4.2%
EC
Average
12,574
291,060
26,084
SD
6,739
118,712
18,331
Positive No.
10
24
13
Positive rate (%)
10.6%
25.5%
13.8%
P (vs. HD)
< 0.001
< 0.001
< 0.05
GC
Average
13,081
264,614
14,297
SD
7,715
97,415
12,101
Positive No.
11
14
2
Positive rate (%)
11.5%
14.6%
2.1%
P (vs. HD)
< 0.001
< 0.01
ns
CRC
Average
11,197
247,181
19,476
SD
6,792
102,736
15,742
Positive No.
7
8
5
Positive rate (%)
7.4%
8.4%
5.3%
P (vs. HD)
ns
ns
ns
Types of cancer diagnoses included esophageal cancer (EC), gastric cancer (GC), and colorectal cancer (CRC). Purified UBE2E3-GST protein, DAN-GST protein, and antigenic SOSTDC1 peptide were used as antigens. Cutoff values were determined as the average HD values plus two SDs. P values were calculated by comparing the results of HDs and patients using the Kruskal–Wallis test. P values < 0.05 and positive rates > 10% are marked in bold. A scatter dot plot of the same results is shown in Figure 1E–G. DAN-Ab: anti-differential screening-selected gene aberrant in neuroblastoma antibody
The authors would like to thank Prof. Masaki Takiguchi (Chiba University), Prof. Kenichiro Kitamura (Yamanishi University), Prof. Hao Wang (Jinan University), Dr. Xiao-Meng Zhang (Chiba University), Dr. Mari Oba (National Center of Neurology and Psychiatry, Tokyo), Dr. Risa Kimura (Chiba University), for supporting this research as well as Ms. Seiko Otsuka, Masae Suzuki, Chiho Kusaka, Satoko Ishibashi, and Akiko Kimura for technical assistance.
The authors declare that they have no conflicts of interest.
Ethical approval
This study was approved by the Local Ethical Review Board of Chiba University, Graduate School of Medicine [approved numbers: 2012-438, 2014-44, 2016-86, 2017-251, 2018-320, 2020-1129, 2022-623, 2023-836], Toho University, Faculty of Medicine [approved numbers: A18103_A17052_A16035_A16001_26095_25024_ 24038_22047, 25131_23005], Toho University Omori Medical Center [approved number: 26-255], and Port Square Kashiwado Clinic [approved number: 2012‑001] as well as by the review boards of the participating hospitals. All experimental procedures were performed in accordance with the Declaration of Helsinki, version 2013.
Consent to participate
Written informed consent was obtained from all participants by following the protocols approved by their institutional ethical committees.
This work was supported, in part, by research grants from the Japan Science and Technology Agency [JST: Exploratory Research No. 14657335], Japan Science and Technology Agency SPRING [grant nos. JPMJSP2109], and research grants from Japan Society for the Promotion of Science KAKENHI [Grant Number: 20K17953, 22K07273, 20K07810, 21K19437, 21K08695, 16K10520]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K, et al. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.Int J Clin Oncol. 2024;29:512–34. [DOI] [PubMed]
Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma.Int J Cancer. 2004;112:1029–35. [DOI] [PubMed]
Kuboshima M, Shimada H, Liu T, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma.Int J Oncol. 2006;28:463–8. [PubMed]
Hou J, Zhao R, Xia W, Chang C, You Y, Hsu J, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.Nat Cell Biol. 2020;22:1264–75. [DOI] [PubMed] [PMC]
Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjogren’s syndrome.Eur J Clin Invest. 2010;40:1026–36. [DOI] [PubMed]
Fularski P, Czarnik W, Dąbek B, Lisińska W, Radzioch E, Witkowska A, et al. Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.Int J Mol Sci. 2024;25:5212. [DOI] [PubMed] [PMC]
Hiwasa T, Machida T, Zhang XM, Kimura R, Wang H, Iwase K, et al. Elevated levels of autoantibodies against ATP2B4 and BMP-1 in sera of patients with atherosclerosis-related diseases.Immunome Res. 2015;11:097. [DOI]
Hiwasa T, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kunimatsu M, et al. Serum SH3BP5-specific antibody level is a biomarker of atherosclerosis.Immunome Res. 2017;13:132. [DOI]
Li S, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, et al. Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis.Sci Rep. 2021;11:13450. [DOI] [PubMed] [PMC]
Hiwasa T, Yoshida Y, Kubota M, Li S, Zhang B, Matsutani T, et al. Serum antiKIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases.Med Int (Lond). 2024;4:45. [DOI] [PubMed] [PMC]
Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview.Eur J Intern Med. 2009;20:663–71. [DOI] [PubMed]
Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications.Arch Med Res. 2017;48:12–26. [DOI] [PubMed]
Hiwasa T, Wang H, Goto K, Mine S, Machida T, Kobayashi E, et al. Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke.BMC Med. 2021;19:131. [DOI] [PubMed] [PMC]
Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients.Am J Nephrol. 2009;29:257–63. [DOI] [PubMed]
Komatsu H, Fujimoto S, Hara S, Fukuda A, Fukudome K, Yamada K, et al. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy.Am J Nephrol. 2009;30:19–25. [DOI] [PubMed]
Goto K, Sugiyama T, Matsumura R, Zhang XM, Kimura R, Taira A, et al. Identification of cerebral infarction-specific antibody markers from autoantibodies detected in patients with systemic lupus erythematosus.J Mol Biomark Diagnos. 2015;6:2. [DOI]
Hamanaka S, Nakagawa T, Hiwasa T, Ohta Y, Kasamatsu S, Ishigami H, et al. Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis.J Gastroenterol Hepatol. 2018;33:1975–83. [DOI] [PubMed]
Naito A, Hiwasa T, Tanabe N, Sanada TJ, Sugiura T, Shigeta A, et al. Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension.PLoS One. 2019;14:e0211377. [DOI] [PubMed] [PMC]
Vermeulen N, de Béeck KO, Vermeire S, Steen KV, Michiels G, Ballet V, et al. Identification of a novel autoantigen in inflammatory bowel disease by protein microarray.Inflamm Bowel Dis. 2011;17:1291–300. [DOI] [PubMed]
Chumpolkulwong N, Sakamoto K, Hayashi A, Iraha F, Shinya N, Matsuda N, et al. Translation of ‘rare’ codons in a cell-free protein synthesis system from Escherichia coli.J Struct Funct Genomics. 2006;7:31–6. [DOI] [PubMed]
Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, et al. Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea.PLoS One. 2018;13:e0195015. [DOI] [PubMed] [PMC]
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.Clin Cancer Res. 2004;10:7252–9. [DOI] [PubMed]
Liu Y, Cai G, Chen P, Jiang T, Xia Z. UBE2E3 regulates cellular senescence and osteogenic differentiation of BMSCs during aging.PeerJ. 2021;9:e12253. [DOI] [PubMed] [PMC]
Sánchez-Duffhues G, Hiepen C, Knaus P, Dijke PT. Bone morphogenetic protein signaling in bone homeostasis.Bone. 2015;80:43–59. [DOI] [PubMed]
Tran LTT, Park H, Kim H. Is the carotid intima-media thickness really a good surrogate marker of atherosclerosis?J Atheroscler Thromb. 2012;19:680–90. [DOI] [PubMed]
Zureik M, Ducimetière P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, et al. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study.Arterioscler Thromb Vasc Biol. 2000;20:1622–9. [DOI] [PubMed]
Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI).J Atheroscler Thromb. 2006;13:101–7. [DOI] [PubMed]
Fan J, Watanabe T. Atherosclerosis: Known and unknown.Pathol Int. 2022;72:151–60. [DOI] [PubMed]
Nakamura R, Tomiyoshi G, Shinmen N, Kuroda H, Kudo T, Doi H, et al. An anti-deoxyhypusine synthase antibody as a marker of atherosclerosis-related cerebral infarction, myocardial infarction, diabetes mellitus, and chronic kidney disease.SM Atheroscler J. 2017;1:1001.
Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, et al. Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases.Cancer Sci. 2020;111:4453–64. [DOI] [PubMed] [PMC]
Li S, Yoshida Y, Kobayashi E, Adachi A, Hirono S, Matsutani T, et al. Association between serum antiASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.Int J Mol Med. 2020;46:1274–88. [DOI] [PubMed] [PMC]
Jarvandi S, Davidson NO, Schootman M. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality.PLoS One. 2013;8:e74616. [DOI] [PubMed] [PMC]
Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T, et al. Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.Int J Oncol. 2015;46:2172–80. [DOI] [PubMed]
Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Physiol Rev. 2015;95:727–48. [DOI] [PubMed] [PMC]
Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, et al. Diabetes and cancer risk: A Mendelian randomization study.Int J Cancer. 2020;146:712–9. [DOI] [PubMed] [PMC]
Zhang C, Yang M. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis.World J Hepatol. 2022;14:956–71. [DOI] [PubMed] [PMC]
Yang Y, Chang Y, Tsai K, Hung M, Kang B. UBE2C triggers HIF-1α-glycolytic flux in head and neck squamous cell carcinoma.J Cell Mol Med. 2022;26:3716–25. [DOI] [PubMed] [PMC]
Ma S, Chen Q, Li X, Fu J, Zhao L. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.Sci Rep. 2023;13:16899. [DOI] [PubMed] [PMC]
Li S, Xue S, Li Z. Osteoporosis: Emerging targets on the classical signaling pathways of bone formation.Eur J Pharmacol. 2024;973:176574. [DOI] [PubMed]
Cai J, Pardali E, Sánchez-Duffhues G, Dijke Pt. BMP signaling in vascular diseases.FEBS Lett. 2012;586:1993–2002. [DOI] [PubMed]
Dyer LA, Pi X, Patterson C. The role of BMPs in endothelial cell function and dysfunction.Trends Endocrinol Metab. 2014;25:472–80. [DOI] [PubMed] [PMC]
Zhang M, Sara JD, Wang F, Liu L, Su L, Zhe J, et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients.Cardiovasc Diabetol. 2015;14:64. [DOI] [PubMed] [PMC]
Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, Hwang J, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response.J Biol Chem. 2003;278:31128–35. [DOI] [PubMed]
Kim CW, Song H, Kumar S, Nam D, Kwon HS, Chang KH, et al. Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells.Arterioscler Thromb Vasc Biol. 2013;33:1350–9. [DOI] [PubMed] [PMC]
Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification.Circ Res. 2010;107:485–94. [DOI] [PubMed] [PMC]
Machida T, Kubota M, Kobayashi E, Iwadate Y, Saeki N, Yamaura A, et al. Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX).J Transl Med. 2015;13:71. [DOI] [PubMed] [PMC]
Braig S, Bosserhoff A. Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression.Oncogene. 2013;32:837–48. [DOI] [PubMed]
Zhou W, Yan K, Xi Q. BMP signaling in cancer stemness and differentiation.Cell Regen. 2023;12:37. [DOI] [PubMed] [PMC]
Sharma T, Kapoor A, Mandal CC. Duality of bone morphogenetic proteins in cancer: A comprehensive analysis.J Cell Physiol. 2022;237:3127–63. [DOI] [PubMed]
Ehata S, Miyazono K. Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.Front Cell Dev Biol. 2022;10:883523. [DOI] [PubMed] [PMC]
Alkhathami AG, Abdullah MR, Ahmed M, Ahmed HH, Alwash SW, Mahdi ZM, et al. Bone morphogenetic protein (BMP)9 in cancer development: mechanistic, diagnostic, and therapeutic approaches?J Drug Target. 2023;31:714–24. [DOI] [PubMed]
